Current Report Filing (8-k)
March 13 2023 - 5:20PM
Edgar (US Regulatory)
0001580149
false
--06-30
0001580149
2023-03-12
2023-03-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): March 12, 2023
BioVie Inc.
(Exact Name of Registrant as Specified in Its
Charter)
Nevada |
|
001-39015 |
|
46-2510769 |
(State
or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(I.R.S.
Employer
Identification No.) |
|
|
|
|
|
680 W Nye Lane Suite 201
Carson City, NV |
|
89703 |
(Address
of Principal Executive Offices) |
|
(Zip
Code) |
(775)
888-3162
(Registrant’s
Telephone Number, Including Area Code)
(Former
Name or Former Address, if Changed Since Last Report)
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
Trading
Symbol(s) |
Name
of each exchange on which registered |
Class
A Common Stock, par value $0.0001 per share |
BIVI |
The Nasdaq Stock Market, LLC |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.03 |
Amendments
to Articles of Incorporation or Bylaws; Change in Fiscal Year. |
On
March 12, 2023, the board of directors of BioVie Inc. (the “Company”) approved and adopted the first amendment (the “First
Amendment”) to the amended and restated bylaws of the Company (the “Bylaws”), which became effective immediately. The
First Amendment amends the Bylaws to (i) provide each of the Chairman of the Board and the Chief Executive Officer with the authority
to call a special meeting of the Board with no less than four hours prior notice and (ii) reduce the required number of directors on
the Board from nine directors to no less than three nor more than eleven.
The
foregoing description of the First Amendment is qualified by reference to the First Amendment, a copy of which is attached hereto as
Exhibit 3.1 and is incorporated herein by reference.
Item
9.01 |
Financial
Statements and Exhibits. |
(d)
Exhibits.
EXHIBIT
INDEX
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
BIOVIE
INC. |
|
|
|
|
By: |
/s/
Joanne Wendy Kim |
|
Name: |
Joanne
Wendy Kim |
|
Title: |
Chief
Financial Officer |
Date:
March 13, 2023
BioVie (NASDAQ:BIVI)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioVie (NASDAQ:BIVI)
Historical Stock Chart
From Jul 2023 to Jul 2024